Share on StockTwits

Shares of Nektar Therapeutics (NASDAQ:NKTR) were the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 10,785,000 shares, an increase of 34.1% from the July 15th total of 8,039,890 shares, American Banking reports. Based on an average daily trading volume, of 1,254,560 shares, the days-to-cover ratio is presently 8.6 days. Currently, 8.6% of the company’s shares are short sold.

A number of research firms have recently commented on NKTR. Analysts at Roth Capital reiterated a “buy” rating on shares of Nektar Therapeutics in a research note on Monday. Separately, analysts at Zacks reiterated an “underperform” rating on shares of Nektar Therapeutics in a research note on Monday, August 4th. They now have a $11.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Nektar Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Friday, July 18th. They now have a $10.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $16.00.

Nektar Therapeutics (NASDAQ:NKTR) traded up 2.61% during mid-day trading on Monday, hitting $12.97. 971,702 shares of the company’s stock traded hands. Nektar Therapeutics has a one year low of $8.87 and a one year high of $15.34. The stock has a 50-day moving average of $12.0 and a 200-day moving average of $12.36. The company’s market cap is $1.651 billion.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings data on Thursday, July 31st. The company reported ($0.26) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.37) by $0.11. The company had revenue of $28.50 million for the quarter, compared to the consensus estimate of $19.76 million. During the same quarter last year, the company posted ($0.37) earnings per share. Nektar Therapeutics’s revenue was down 15.9% compared to the same quarter last year. On average, analysts predict that Nektar Therapeutics will post $-0.64 earnings per share for the current fiscal year.

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.